These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 28701569)

  • 21. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.
    Buisseret L; Desmedt C; Garaud S; Fornili M; Wang X; Van den Eyden G; de Wind A; Duquenne S; Boisson A; Naveaux C; Rothé F; Rorive S; Decaestecker C; Larsimont D; Piccart-Gebhart M; Biganzoli E; Sotiriou C; Willard-Gallo K
    Mod Pathol; 2017 Sep; 30(9):1204-1212. PubMed ID: 28621322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
    Seow DYB; Yeong JPS; Lim JX; Chia N; Lim JCT; Ong CCH; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2020 Apr; 180(2):369-377. PubMed ID: 32034580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.
    Tsang JY; Ho CS; Ni YB; Shao Y; Poon IK; Chan SK; Cheung SY; Shea KH; Marabi M; Tse GM
    Cancer Immunol Immunother; 2020 May; 69(5):799-811. PubMed ID: 32055918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy.
    Wang Q; Sun K; Liu R; Song Y; Lv Y; Bi P; Yang F; Li S; Zhao J; Li X; Chen D; Mei J; Yang R; Chen K; Liu D; Tang S
    Clin Transl Med; 2023 Aug; 13(8):e1346. PubMed ID: 37525587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
    Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
    Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-A
    Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
    Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes.
    Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Otsuka H; Kanomata N; Minami S; Eguchi S; Yano H
    J Clin Pathol; 2016 Oct; 69(10):890-8. PubMed ID: 27030304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
    Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer Microenvironment Defines Tumor-Infiltrating Lymphocyte Density and Tertiary Lymphoid Structure Formation in Laryngeal Cancer.
    Gkegka AG; Koukourakis MI; Katotomichelakis M; Giatromanolaki A
    Head Neck Pathol; 2023 Jun; 17(2):422-432. PubMed ID: 36586079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer.
    Abe N; Matsumoto H; Takamatsu R; Tamaki K; Takigami N; Uehara K; Kamada Y; Tamaki N; Motonari T; Unesoko M; Nakada N; Zaha H; Yoshimi N
    Virchows Arch; 2020 May; 476(5):701-709. PubMed ID: 31873876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
    Sofopoulos M; Fortis SP; Vaxevanis CK; Sotiriadou NN; Arnogiannaki N; Ardavanis A; Vlachodimitropoulos D; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2019 Nov; 68(11):1733-1745. PubMed ID: 31598757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.
    Berthe J; Poudel P; Segerer FJ; Jennings EC; Ng F; Surace M; Andoni A; Testori M; Saraiya M; Vuko M; Hessel H; Heininen-Brown M; Blando J; Jones EV; Willis SE; Galon J; van de Ven R; de Gruijl TD; Angell HK
    Front Immunol; 2024; 15():1422206. PubMed ID: 39376565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between
    Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
    Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
    Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.